Back to results
US 12,740,966 B2Granted
Method for improving bioavailability of NAD+ derivatives
AssigneeHoboomlife Bio-Technology (Shenzhen) Co., Ltd.
InventorsJiansheng Chen, Yaying Hou, Tong Zhang, Jing Lyu, Yuqin Bai
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method for improving bioavailability of an NAD+ derivative. The method improves the bioavailability of the NAD+ derivative by arranging a CD38 inhibitor and the NAD+ derivative in a same preparation, and controlling the CD38 inhibitor to release first rapidly, and then the NAD+ derivative releases after the CD38 inhibitor has taken effect, thereby increasing the level of NAD+ in vivo.
Claims7
A method for improving bioavailability of an NAD+ derivative, comprising:
- administering microspheres into a subject, wherein the microspheres each comprise:
- a) a pellet core comprising the NAD+ derivative and an excipient for controlled release selected from at least one of:
- a hydrophilic gel material and a bioerodible material;
- and
- b) a coating comprising a CD38 inhibitor and a filler;
- wherein an outer surface of the pellet core is wrapped with the coating;
- wherein the CD38 inhibitor is selected from at least one of:
- quercetin, apigenin, resveratrol, grape seed extract, strawberry extract, and cocoa extract;
- wherein the NAD+ derivative is selected from at least one of:
- nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinamide (NAM), and nicotinamide adenine dinucleotide (NADH);
- and
- wherein the CD38 inhibitor and the NAD+ derivative in the microsphere are released stepwise in such a manner that the CD38 inhibitor releases first and then the NAD+ derivative releases.
9 more elements
Dependencies are inferred from the claim text.